|
|
Volumn 348, Issue , 2014, Pages
|
|
NICE says drug for metastatic breast cancer is unaffordable for NHS.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
MONOCLONAL ANTIBODY;
TRASTUZUMAB;
ADVISORY COMMITTEE;
BREAST TUMOR;
COST BENEFIT ANALYSIS;
DRUG APPROVAL;
ECONOMICS;
FEMALE;
HUMAN;
METASTASIS;
NATIONAL HEALTH SERVICE;
NOTE;
UNITED KINGDOM;
ADVISORY COMMITTEES;
ANTIBODIES, MONOCLONAL, HUMANIZED;
ANTINEOPLASTIC AGENTS;
BREAST NEOPLASMS;
COST-BENEFIT ANALYSIS;
DRUG APPROVAL;
FEMALE;
GREAT BRITAIN;
HUMANS;
STATE MEDICINE;
|
|
EID: 84901714221
PISSN: None
EISSN: 17561833
Source Type: Journal
DOI: 10.1136/bmj.g2888 Document Type: Note |
|
Times cited : (4)
|
|
References (0)
|
